MXPA05007691A - Procedimiento para modificar la formacion de cristal de farmaco. - Google Patents

Procedimiento para modificar la formacion de cristal de farmaco.

Info

Publication number
MXPA05007691A
MXPA05007691A MXPA05007691A MXPA05007691A MXPA05007691A MX PA05007691 A MXPA05007691 A MX PA05007691A MX PA05007691 A MXPA05007691 A MX PA05007691A MX PA05007691 A MXPA05007691 A MX PA05007691A MX PA05007691 A MXPA05007691 A MX PA05007691A
Authority
MX
Mexico
Prior art keywords
crystal formation
drug crystal
modifying drug
modifying
crystals
Prior art date
Application number
MXPA05007691A
Other languages
English (en)
Inventor
Wieckhusen Dierk
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05007691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05007691A publication Critical patent/MXPA05007691A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)

Abstract

Se describe un procedimiento para modificar el habito de cristal de sustancias de farmaco aciculares, cristales obtenidos a traves de dicho procedimiento, y formas de cristal particulares o modificaciones de acido micofenolico o micofenolato de sodio, asi como composiciones farmaceuticas que comprenden los cristales, metodos y tratamiento y usos de los mismos.
MXPA05007691A 2003-01-20 2004-01-19 Procedimiento para modificar la formacion de cristal de farmaco. MXPA05007691A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation

Publications (1)

Publication Number Publication Date
MXPA05007691A true MXPA05007691A (es) 2005-09-30

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007691A MXPA05007691A (es) 2003-01-20 2004-01-19 Procedimiento para modificar la formacion de cristal de farmaco.

Country Status (32)

Country Link
US (3) US20060122265A1 (es)
EP (2) EP1592401B1 (es)
JP (1) JP4549976B2 (es)
KR (5) KR20100120321A (es)
CN (2) CN101333201A (es)
AR (2) AR043343A1 (es)
AT (1) ATE546132T1 (es)
AU (1) AU2004206731B2 (es)
BR (1) BRPI0406827A (es)
CA (2) CA2509796C (es)
CL (1) CL2004000073A1 (es)
CO (1) CO5580738A2 (es)
CY (1) CY1112772T1 (es)
DK (1) DK1592401T3 (es)
EC (1) ECSP055918A (es)
ES (1) ES2382035T3 (es)
GB (1) GB0301259D0 (es)
HK (1) HK1084874A1 (es)
IL (1) IL169484A (es)
MX (1) MXPA05007691A (es)
MY (1) MY148297A (es)
NO (1) NO20053846L (es)
NZ (1) NZ541073A (es)
PE (2) PE20040826A1 (es)
PL (2) PL376525A1 (es)
PT (1) PT1592401E (es)
RU (1) RU2388757C2 (es)
SG (1) SG155046A1 (es)
SI (1) SI1592401T1 (es)
TW (1) TWI325785B (es)
WO (1) WO2004064806A2 (es)
ZA (1) ZA200504442B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
WO2005105768A2 (en) 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105769A2 (en) 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
CA2573781A1 (en) 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
MX2011003731A (es) * 2008-10-09 2011-08-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Uso de solventes organicos en la granulacion humeda de moxifloxacino.
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
HUE030116T2 (en) 2011-04-13 2017-04-28 Janssen Pharmaceutica Nv A method for preparing compounds useful as inhibitors of SGLT2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
PL3394051T3 (pl) * 2015-12-21 2020-10-19 Janssen Pharmaceutica N.V. Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
DE69321531T2 (de) * 1992-08-04 1999-03-04 Toda Kogyo Corp Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
DK0724581T3 (da) 1993-09-15 1999-08-02 Syntex Inc Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR100855149B1 (ko) 2008-08-28
EP1592401B1 (en) 2012-02-22
IL169484A0 (en) 2007-07-04
NO20053846L (no) 2005-08-16
RU2388757C2 (ru) 2010-05-10
PL376525A1 (pl) 2006-01-09
CN100595199C (zh) 2010-03-24
AU2004206731B2 (en) 2008-03-20
KR20090115821A (ko) 2009-11-06
IL169484A (en) 2016-03-31
CN1738605A (zh) 2006-02-22
CL2004000073A1 (es) 2005-01-14
US20110288313A1 (en) 2011-11-24
JP4549976B2 (ja) 2010-09-22
AR103711A2 (es) 2017-05-31
JP2006515016A (ja) 2006-05-18
ES2382035T3 (es) 2012-06-04
SG155046A1 (en) 2009-09-30
HK1084874A1 (en) 2006-08-11
CO5580738A2 (es) 2005-11-30
WO2004064806A2 (en) 2004-08-05
NZ541073A (en) 2008-12-24
AR043343A1 (es) 2005-07-27
GB0301259D0 (en) 2003-02-19
US20060122265A1 (en) 2006-06-08
EP1592401A2 (en) 2005-11-09
KR20100120321A (ko) 2010-11-15
KR20050096940A (ko) 2005-10-06
WO2004064806A3 (en) 2004-10-28
KR20090115898A (ko) 2009-11-09
AU2004206731A1 (en) 2004-08-05
KR101129105B1 (ko) 2012-04-12
US8124795B2 (en) 2012-02-28
PE20040826A1 (es) 2004-12-23
DK1592401T3 (da) 2012-05-21
TW200505505A (en) 2005-02-16
KR20070087181A (ko) 2007-08-27
BRPI0406827A (pt) 2005-12-27
CY1112772T1 (el) 2016-02-10
CA2509796A1 (en) 2004-08-05
CA2509796C (en) 2010-09-14
SI1592401T1 (sl) 2012-05-31
EP2308471A1 (en) 2011-04-13
US8008511B2 (en) 2011-08-30
TWI325785B (en) 2010-06-11
PE20110276A1 (es) 2011-05-27
PL213192B1 (pl) 2013-01-31
ATE546132T1 (de) 2012-03-15
PL393385A1 (pl) 2011-03-14
PT1592401E (pt) 2012-05-10
AU2004206731A8 (en) 2004-08-05
CN101333201A (zh) 2008-12-31
MY148297A (en) 2013-03-29
CA2706900A1 (en) 2004-08-05
RU2005126328A (ru) 2006-07-27
US20090209639A1 (en) 2009-08-20
ECSP055918A (es) 2005-11-22
ZA200504442B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
SG155046A1 (en) Process for modifying drug crystal formation
CY1118637T1 (el) Νεα κρυσταλλικη μορφη iii της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
SE0200920D0 (sv) Novel compounds
WO2006086562A3 (en) Phenylazetidinone derivatives
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
HK1090042A1 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the of the same as medicaments, and medicament containing such compounds
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
SI1751093T1 (sl) Substituirani derivati cikloheksilocetne kisline
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
WO2004019879A8 (en) Motilide compounds
WO2005046727A3 (en) Ibuprofen-containing soft gelatin capsules
NO20053673L (no) Nye antikonvulsanderivatsalter
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
WO2004033416A3 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2005014542A3 (de) Neue n-substituierte indolyl-3-glyoxylsäureamide, deren verwendung als arzneimittel gegen krebs und verfahren zu deren herstellung
WO2005020911A3 (en) Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same
SE0400522D0 (sv) A medical solution, a method for producing said medical solution and use thereof
WO2006122771A3 (de) Substituierte benzokondensierte cyclohexanon-derivate und deren verwendung zur herstellung von arzneimitteln zur behandlung von schmerz

Legal Events

Date Code Title Description
FG Grant or registration